Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma Inc (NQ: INZY )

4.700 +0.100 (+2.17%)
Streaming Delayed Price Updated: 11:25 AM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inozyme Pharma Inc

< Previous 1 2 3 4 5 Next >
4 Analysts Have This to Say About Inozyme Pharma
Via Benzinga
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
Analyst Ratings for Inozyme Pharma
Via Benzinga
4 Analysts Have This to Say About Inozyme Pharma
Via Benzinga
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the Jefferies Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Recap: Inozyme Pharma Q1 Earnings
Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated... 
Via Benzinga
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
From Inozyme Pharma Inc.
Via GlobeNewswire
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ... 
Via Benzinga
Why Safe & Green Holdings Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Gainers Boxed, Inc. (NYSE: BOXD) gained 43.3% to $0.2303 in pre-market trading after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S.... 
Via Benzinga
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
Via Benzinga
89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday
Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose... 
Via Benzinga
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.